MedTrace Logo

Exploring the Molecular Mechanism Based on KIT Mutation

NCT05895942 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 190

Last updated 2023-06-09

No results posted yet for this study

Summary

Imatinib remains suboptimal for recurrence/metastasis and unresectable GIST response rates. With the maturity of genomics and metabolomics, people gradually realize the role of gut microbiota in tumor therapy. The gut microbiota may affect tumor treatment by regulating the tumor microenvironment or the host immune system, and some bacteria can fight tumors by activating the immune system. Growing evidence shows that the effect of tumor therapy is related to the composition of the gut microbiota of patients, and that the composition of the gut microbiota of patients sensitive to drug treatment has certain characteristics, and these characteristics may be used as biomarkers to predict the prognosis of treatment. At present, it remains unclear whether the efficacy of imatinib is related to the gut microbiota in GIST patients. Therefore, precise mining of microbial information and the development of reasonable and feasible microbial interventions are expected to optimize the treatment strategy of GIST to a large extent and provide a basis for individualized treatment of advanced GIST.

Conditions

Interventions

DRUG

Imatinib

The control group, before and after imatinib treatment, and patients with different efficacy of imatinib treatment were collected, and the correlation analysis was performed to screen the key flora and metabolites that affect the efficacy of imatinib

Sponsors & Collaborators

  • Xijing Hospital

    lead OTHER

Principal Investigators

  • jun j Yang, Master · The First Affiliated Hospital of Air Force Medicial University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-10
Primary Completion
2024-09-10
Completion
2025-09-10

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05895942 on ClinicalTrials.gov